Comparison of in vitro susceptibility of Sarcoptes scabiei var.hominis to topical 5%permethrin and topical 1% ivermectin
DOI:
https://doi.org/10.66344/jpad.v26i2.49Keywords:
Scabies, Sarcoptes scabiei, ivermectin, permethrin, in vitro susceptibilityAbstract
Objective: To compare the in vitro susceptibility of Sarcoptes scabiei var.hominis to 5% permethrin and 1% ivermectin.
Methods: A randomized, controlled trial was conducted in OPD, Dermatology Department, Military Hospital, Rawalpindi, Pakistan over a period of six months from December 17, 2014 to June 16, 2015.A total of 80 mites from 80 patients were taken. Mites were randomly allocated to two groups: group A (5% permethrin) and group B (1% ivermectin). 5% permethrin and 1% ivermectin were applied in a thin film over a glass slide. Live mites were gently transferred to the glass slide. These were inspected microscopically for leg movements at an hourly interval for 6 hours. Death was declared once all leg movements had ceased. All mites which died within 6 hours were considered as susceptible to drug, while mites having active leg movements even after 6 hours were considered as non-susceptible.
Results: There were 35 (84.5%) mites which showed invitro susceptibility in the group A (5% permethrin), whereas all the mites from group B (1% ivermectin) were susceptible.
Conclusion: The in vitro susceptibility was statistically significant (p=0.021) in both the groups. 1% ivermectin was better than 5% permethrin in terms of invitro susceptibility.
References
1. Fuller LC. Epidemiology of scabies. Curr Opin Infect Dis. 2013;26:123-6.
2. Heukelbach J, Mazigo HD, Ugbomoiko US. Impact of scabies in resource-poor communities. Curr Opin Infect Dis. 2013;26:127-32.
3. Hay RJ, Steer AC, Engelman D, Walton S. Scabies in the developing world--its prevalence, complications, and management. Clin Microbiol Infect. 2012;18:313-23.
4. Micali G, Lacarrubba F, Verzì AE, Nasca MR. Low-cost equipment for diagnosis and management of endemic scabies outbreaks in underserved populations. Clin Infect Dis. 2015;60:327-9.
5. Leung V, Miller M. Detection of scabies: A systematic review of diagnostic methods. Can J Infect Dis Med Microbiol. 2011;22:143-6.
6. Le Cleach L, Chosidow O. Commentary on "Interventions for treating scabies". Evid Based Child Health. 2011;6:1865-6.
7. Ranjkesh MR, Naghili B, Goldust M, Rezaee E. The efficacy of permethrin 5% vs. oral ivermectin for the treatment of scabies. Ann Parasitol. 2012;59:189-94.
8. Lokuge B, Kopczynski A, Woltmann A, Alvoen F, Connors C, Guyula T et al. Crusted scabies in remote Australia, a new way forward: lessons and outcomes from the East Arnhem Scabies Control Program. Med J Aust. 2014;200:644-8.
9. Gonzalez P, González F, Ueno K. Ivermectin in human medicine, an overview of the current status of its clinical applications. Curr Pharm Biotechnol. 2012;13:1103-9.
10. Thuan NH, Pandey RP, Sohng JK. Recent advances in biochemistry and biotechnological synthesis of avermectins and their derivatives. Appl Microbiol Biotechnol. 2014;98:7747-59.
11. Ōmura S, Crump A. Ivermectin: panacea for resource-poor communities? Trends Parasitol. 2014;30:445-55.
12. Webster JP, Molyneux DH, Hotez PJ, Fenwick A. The contribution of mass drug administration to global health: past, present and future. Philos Trans R Soc Lond B Biol Sci. 2014;369:20130434.
13. Rizvi SDA, Iftikhar N, Batool F. Effectiveness of oral ivermectin for eradicating infesting mites in patients of scabies. J Pak Assoc Dermatol. 2011;21:87-92.
14. Goldust M, Rezaee E, Raghifar R, Hemayat S. Treatment of scabies: the topical ivermectin vs. permethrin 2.5% cream. Ann Parasitol. 2013;59:79-84.
15. Chhaiya SB, Patel VJ, Dave JN, Mehta DS, Shah HA. Comparative efficacy and safety of topical permethrin, topical ivermectin, and oral ivermectin in patients of uncomplicated scabies. Indian J Dermatol Venereol Leprol. 2012;78:605-10.
16. Alasaad S, Rossi L, Heukelbach J, Pérez JM, Hamarsheh O, Otiende M et al. The neglected navigating web of the incomprehensibly emerging and re-emerging Sarcoptes mite. Infect Genet Evol. 2014;17:253-9.
17. Andriantsoanirina V, Izri A, Botterel F, Foulet F, Chosidow O, Durand R. Molecular survey of knockdown resistance to pyrethroids in human scabies mites. Clin Microbiol Infect. 2014;20:O139-O141.
18. Dong K, Du Y, Rinkevich F, Nomura Y, Xu P, Wang L et al. Molecular biology of insect sodium channels and pyrethroid resistance. Insect Biochem Mol Biol. 2014;50:1-17.
19. Fischer K, Holt D, Currie B, Kemp D. Scabies: Important clinical consequences explained by new molecular studies. Adv Parasitol. 2012;79:339-73.
20. Chhaiya SB, Mehta DS, Kataria BC. Ivermectin: pharmacology and therapeutic applications. Int J Basic Clin Pharmacol. 2012; 1:132-9.
21. Aggarwal G, Rathore PK. Comparative study to test efficacy of topical permethrin and oral ivermectin in the management of scabies-a prospective randomized, single blinded controlled study. Nat J Integ Res Med. 2014;5:57-60.
22. Stoevesandt J, Carlé L, Leverkus M, Hamm H. Control of large institutional scabies outbreaks. J Dtsch Dermatol Ges. 2012;10:637-47.
23. Worth C, Heukelbach J, Fengler G, Walter B, Liesenfeld O et al. Acute morbidity associated with scabies and other ectoparasitoses rapidly improves after treatment with ivermectin. Pediatr Dermatol. 2012;29:430-6.
24. Elston CA, Elston DM. Treatment of common skin infections and infestations during pregnancy. Dermatol Ther. 2013;26:312-20.
25. Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. J Am Acad Dermatol. 2014;70:417-e1.
26. Fujimoto K, Kawasaki Y, Morimoto K, Kikuchi I, Kawana S. Treatment for crusted scabies: limitations and side effects of treatment with ivermectin. J Nippon Med Sch. 2014;81:157-63.
27. Manjhi PK, Sinha RI, Kumar M, Sinha KI. Comparative study of efficacy of oral ivermectin versus some topical antiscabies drugs in the treatment of scabies. J Clin Diagn Res. 2014;8: HC01-4.
28. Haas N, Lindemann U, Frank K, Sterry W, Lademann J, Katzung W. Rapid and preferential sebum secretion of ivermectin: a new factor that may determine drug responsiveness in patients with scabies. Arch Dermatol. 2002;138:1618-9.
29. Miyajima A, Komoda M, Akagi K, Yuzawa K, Yoshimasu T, Yamamoto Y et al. Experimental study of pharmacokinetics of external, whole‐body bathing application of ivermectin. J Dermatol. 2015;42:87-89.
30. Walton SF, Myerscough MR, Currie BJ. Studies in vitro on the relative efficacy of current acaricides for Sarcoptes scabiei var. hominis. Trans R Soc Trop Med Hyg. 2000;94:92-6.
Downloads
Published
Issue
Section
License
Copyright (c) 2016 Nighat Akbar, Nadia Iftikhar
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
